riboflavin carrier protein
Recently Published Documents


TOTAL DOCUMENTS

59
(FIVE YEARS 1)

H-INDEX

13
(FIVE YEARS 1)

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 295 ◽  
Author(s):  
Milita Darguzyte ◽  
Natascha Drude ◽  
Twan Lammers ◽  
Fabian Kiessling

Active targeting can improve the retention of drugs and drug delivery systems in tumors, thereby enhancing their therapeutic efficacy. In this context, vitamin receptors that are overexpressed in many cancers are promising targets. In the last decade, attention and research were mainly centered on vitamin B9 (folate) targeting; however, the focus is slowly shifting towards vitamin B2 (riboflavin). Interestingly, while the riboflavin carrier protein was discovered in the 1960s, the three riboflavin transporters (RFVT 1-3) were only identified recently. It has been shown that riboflavin transporters and the riboflavin carrier protein are overexpressed in many tumor types, tumor stem cells, and the tumor neovasculature. Furthermore, a clinical study has demonstrated that tumor cells exhibit increased riboflavin metabolism as compared to normal cells. Moreover, riboflavin and its derivatives have been conjugated to ultrasmall iron oxide nanoparticles, polyethylene glycol polymers, dendrimers, and liposomes. These conjugates have shown a high affinity towards tumors in preclinical studies. This review article summarizes knowledge on RFVT expression in healthy and pathological tissues, discusses riboflavin internalization pathways, and provides an overview of RF-targeted diagnostics and therapeutics.


Biomaterials ◽  
2012 ◽  
Vol 33 (34) ◽  
pp. 8822-8829 ◽  
Author(s):  
Jabadurai Jayapaul ◽  
Susanne Arns ◽  
Wiltrud Lederle ◽  
Twan Lammers ◽  
Peter Comba ◽  
...  

2006 ◽  
Vol 35 (2) ◽  
pp. 83-87 ◽  
Author(s):  
P RAO ◽  
J CRIPPIN ◽  
E LEVINE ◽  
J HUNT ◽  
S BALIGA ◽  
...  

2006 ◽  
Vol 317 (2) ◽  
pp. 465-472 ◽  
Author(s):  
Clifford W. Mason ◽  
Vanessa M. D'Souza ◽  
Lisa M. Bareford ◽  
Mitch A. Phelps ◽  
Abhijit Ray ◽  
...  

Reproduction ◽  
2005 ◽  
Vol 129 (5) ◽  
pp. 577-587
Author(s):  
A Sreekumar ◽  
K K Acharya ◽  
H S Lalitha ◽  
S S Indi ◽  
P Bali ◽  
...  

Riboflavin carrier protein (RCP) is a phosphoglycoprotein (37 kDa) that is well studied in chicken. An immunologically cross-reacting protein was identified in mammals and active immunization of male rats and bonnet monkeys with chicken RCP lead to an ∼80% reduction in fertility. However, the physiological mechanism responsible for inhibition of male fertility has not been investigated. Moreover, information on the cell type-specific localization and the origin of immunoreactive RCP during spermatogenesis is extremely limited. Hence, studies were carried out to determine the pattern of expression of immunoreactive RCP during spermatogenesis and its role in sperm function in the golden hamster. Immunoreactive RCP was germ cell-specific, found to be associated with the acrosome-organizing region of early spermatids and showed interesting patterns of immunolocalization during late stages of spermiogenesis. Mature spermatozoa exhibited acrosome-specific localization, mainly in the peri-acrosomal membrane. The immunoreactive protein was undetectable in (non)gonadal somatic cells tested. The protein had a molecular mass of 45–55 kDa and was biosynthesized by round spermatids. The acrosome-specific localization of immunoreactive RCP was unchanged during capacitation, but it was substantially lost during acrosome reaction. Functional studies indicated that treatment of spermatozoa with anti-RCP antibodies did not have any effect on either capacitation or acrosome reaction, but markedly reduced the rate of sperm penetration into zona-free hamster oocytes. These results show the existence of male germ cell-specific immunoreactive RCP, having a potential role in sperm–egg interaction in hamsters. Also the pattern of immunoreactive-RCP localization makes it an ideal marker to monitor development of acrosome in mammalian spermatozoa.


Sign in / Sign up

Export Citation Format

Share Document